Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10846854 | 0.98 | LMNA (0.36) | LMNADPP4ALDH1A1 | |
| SCHEMBL248308 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL9422815 | 0.80 | — | — | |
| SCHEMBL21938458 | 0.80 | LMNA (0.36) | LMNADPP4 | |
| SCHEMBL12436912 | 0.80 | LMNA (0.36) | LMNADPP4ALDH1A1 | |
| SCHEMBL2087384 | 0.78 | ALDH1A1 (0.40) | ALDH1A1 | |
| SCHEMBL5551595 | 0.78 | — | — | |
| SCHEMBL10847408 | 0.77 | TSHR (0.36) | ALDH1A1 | |
| SCHEMBL24770416 | 0.77 | LMNA (0.34) | LMNADPP4ALDH1A1 | |
| SCHEMBL2275815 | 0.76 | ALDH1A1 (0.44) | LMNADPP4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306287-A1 | Process for Preparing Tetrahydropyran-4-Carboxylic Acid Compound | UBE INDUSTRIES, LTD. (JP) | 2008-12-11 | — | — | US | claimed |
| EP-4727938-A1 | BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING NEUROLOGICAL DISORDERS | Prothena Biosciences Limited (IE) | 2026-04-22 | — | — | EP | disclosed |
| EP-3858833-B9 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2026-03-11 | — | — | EP | disclosed |
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | CELLARITY, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| EP-3858833-B1 | AMINONORBORNANE DERIVATIVE AND MANUFACTURE METHOD THEREOF AND USE THEREOF | TRANSTHERA SCIENCES NANJING INC (CN) | 2025-10-22 | — | — | EP | disclosed |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | ONCO3R THERAPEUTICS BV (BE) | 2025-08-19 | — | — | US | disclosed |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-08-14 | — | — | US | disclosed |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | THAMES PHARMA PARTNERS | 2025-05-22 | — | — | US | disclosed |
| WO-2025096956-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | CELLARITY, INC. (US) | 2025-05-08 | — | — | WO | disclosed |
| US-12291534-B2 | Aminonorbornane derivative and manufacture method therefor and use thereof | TRANSTHERA SCIENCES (NANJING), INC. (CN) | 2025-05-06 | — | — | US | disclosed |
| US-7300953-B2 | Process for preparing nitrile compound, carboxylic acid compound or carboxylic acid ester compound | UBE INDUSTRIES, LTD (JP) | 2007-11-27 | — | — | US | disclosed |
| EP-1856110-A1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | Pfizer, Inc. (US) | 2007-11-21 | — | — | EP | disclosed |
| CN-101061102-A | Process for producing tetrahydropyran-4-carboxylic acid compound | UBE INDUSTRIES (JP) | 2007-10-24 | — | — | CN | disclosed |
| US-20070043107-A1 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | UBE INDUSTRIES, LTD. (JP) | 2007-02-22 | — | — | US | disclosed |
| US-20060287541-A1 | Subjecting a 4-substituted tetrahydropyran-4-carboxylic acid compound to to decarboxylation in the presence of a metal catalyst for producing 4-substituted tetrahydropyran | UBE INDUSTRIES, LTD. (JP) | 2006-12-21 | — | — | US | disclosed |
| EP-1700852-A1 | PROCESSES FOR PRODUCING ALKYL 3-(4-TETRAHYDROPYRANYL)-3-OXOPROPIONATE COMPOUND AND 4-ACYLTETRAHYDROPYRAN | Ube Industries, Ltd. (JP) | 2006-09-13 | — | — | EP | disclosed |
| US-20060194842-A1 | Oxyindole derivatives | PFIZER INC. | 2006-08-31 | — | — | US | disclosed |
| WO-2006090279-A1 | OXYINDOLE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER JAPAN INC. (JP) | 2006-08-31 | — | — | WO | disclosed |
| EP-1671937-A1 | METHOD FOR PRODUCING NITRILE COMPOUND, CARBOXYLIC ACID COMPOUND OR CARBOXYLATE COMPOUND | Ube Industries, Ltd. (JP) | 2006-06-21 | — | — | EP | disclosed |
| WO-2006054688-A1 | PROCESS FOR PRODUCING TETRAHYDROPYRAN-4-CARBOXYLIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060287541-A1 | Subjecting a 4-substituted tetrahydropyran-4-carboxylic acid compound to to decarboxylation in the presence of a metal catalyst for producing 4-substituted tetrahydropyran | CBR1, ALDH18A1, ME1 | LMNA 4534/4885DPP4 1881/4885ALDH1A1 39/4885 |
| US-12473285-B2 | DCN-1 modulating compounds and methods of use thereof | DCUN1D1, DCUN1D2, DCUN1D4 | LMNA 2115/4885DPP4 3868/4885ALDH1A1 822/4885 |
| US-20080306287-A1 | Process for Preparing Tetrahydropyran-4-Carboxylic Acid Compound | ADH1A, ADH1C, HPD | LMNA 4054/4885DPP4 951/4885ALDH1A1 29/4885 |
| US-12291534-B2 | Aminonorbornane derivative and manufacture method therefor and use thereof | BTK, LCK, SYK | LMNA 3192/4885DPP4 4466/4885ALDH1A1 3912/4885 |
| US-20070043107-A1 | Processes for preparing alkyl 3-(4-tetrahydropyranyl)-3-oxopropanoate compound and 4-acyltetrahydropyrane | DHPS, OXER1, CYP4A11 | LMNA 3899/4885DPP4 1140/4885ALDH1A1 312/4885 |
| US-20060194842-A1 | Oxyindole derivatives | HTR4, HTR5A, HRH4 | LMNA 4515/4885DPP4 295/4885ALDH1A1 2553/4885 |
| US-20250163057-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | LMNA 2115/4885DPP4 3868/4885ALDH1A1 822/4885 |
| US-12391679-B2 | Benzamide-substituted bicyclic imidazo- and pyrazolo-fused -pyridine, -pyrimide, and -pyridazine compounds for treatment of inflammatory diseases | IL5, IL15, IL1A | LMNA 1910/4885DPP4 1054/4885ALDH1A1 1043/4885 |
| US-20250257063-A1 | DCN-1 MODULATING COMPOUNDS AND METHODS OF USE THEREOF | DCUN1D1, DCUN1D2, DCUN1D4 | LMNA 2115/4885DPP4 3868/4885ALDH1A1 822/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.